Experiment Overview
| Repository ID: | FR-FCM-Z63W | Experiment name: | RESCEU - Peripheral Blood Mononuclear Cell Profiling using custom panel | MIFlowCyt score: | 35.75% |
| Primary researcher: | Yann Abraham | PI/manager: | Yann Abraham | Uploaded by: | Yann Abraham |
| Experiment dates: | 2023-02-17 - | Dataset uploaded: | Feb 2023 | Last updated: | Dec 2024 |
| Keywords: | [CyTOF] [infectious disaese] [RSV] [RESCEU] | Manuscripts: | |||
| Organizations: |
Janssen Pharmaceutical Companies of Johnson & Johnson, Janssen Research & Development, Turnhout, (Belgium)
|
||||
| Purpose: | Respiratory syncytial virus (RSV) infection is the leading global cause of hospitalization and mortality in infants with severe acute respiratory tract infections (ARTI). A detailed understanding of cellular and molecular biomarkers in severe RSV disease will support the ongoing research of predicting disease severity in clinics by using an objective biomarker along with the clinical parameters and stratification of infants by disease severity in investigational therapeutics and vaccines.One objective of the European Commission-funded REspiratory Syncytial virus Consortium of EUrope (RESCEU; https://resc-eu.org) is to identify biomarkers of RSV disease severity in infants to aid clinical management. Whole blood samples were collected from the multinational RESCEU infant case-control study and RESCEU birth cohort study. We investigated single-cell immune profiles in whole blood of infants with various clinical manifestations of RSV infection using a novel 42-marker CyTOF panel, allowing simultaneous exploration of cells that carry out innate and adaptive immune responses, including B cell, T cell, monocyte, and neutrophil cell subsets. | ||||
| Conclusion: | None | ||||
| Comments: | None | ||||
| Funding: | Not disclosed | ||||
| Quality control: | None | ||||
